You just read:

The Lancet Infectious Diseases Journal Publishes Results of Phase 2 Study of Lonafarnib in Hepatitis Delta Virus (HDV) Infected Patients

News provided by

Eiger BioPharmaceuticals, Inc.

Jul 20, 2015, 08:00 ET